Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 June 2020Website:
http://www.lanternpharma.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 33 min agoDividend
Analysts recommendations
Institutional Ownership
LTRN Latest News
Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Dr. Reggie Ewesuedo - Vice President, Clinical Development Conference Call Participants John Vandermosten - Zacks Research Operator Good afternoon. And welcome to our Second Quarter 2024 Earnings Call.
Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Panna Sharma - President and Chief Executive Officer David Margrave - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to our Third Quarter 2023 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode.
The artificial intelligence ( AI ) boom is far from over. For example let's look at Nvidia (NASDAQ: NVDA ), where CEO Jensen Huang still believes his stock is wildly undervalued.
Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Nicole Leber – Investor Relations Panna Sharma – Chief Executive Officer David Margave – Chief Financial Officer Conference Call Participants Nicole Leber Good afternoon, everyone. I'm Nicole Leber with Investor Relations here at Lantern Pharma.
As we forge ahead into the AI era, the top AI penny stocks have become increasingly relevant, emerging as a buzzword among savvy investors. Projected to inject a massive $15.7 trillion into the global economy by the conclusion of the current decade, AI is no longer just the playground for large-cap tech giants.
The bull market in artificial intelligence is just getting started. In fact, with the boom only set to accelerate, we may be looking at a $1.81 trillion opportunity by 2030, says Grand View Research.
AI penny stocks offer investors a thrilling opportunity to tap into the fast-evolving artificial intelligence space. AI penny stocks have limited financial resources and modest profits, but their long-term growth prospects are enticing.
Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Officer and President David Margrave - Chief Financial Officer and Secretary Conference Call Participants Michael King - EF Hutton Nicole Leber Good afternoon, everyone. I'm Nicole Weber with Investor Relations here at Lantern Pharma.
What type of business is Lantern Pharma?
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
What sector is Lantern Pharma in?
Lantern Pharma is in the Healthcare sector
What industry is Lantern Pharma in?
Lantern Pharma is in the Biotechnology industry
What country is Lantern Pharma from?
Lantern Pharma is headquartered in United States
When did Lantern Pharma go public?
Lantern Pharma initial public offering (IPO) was on 11 June 2020
What is Lantern Pharma website?
https://www.lanternpharma.com
Is Lantern Pharma in the S&P 500?
No, Lantern Pharma is not included in the S&P 500 index
Is Lantern Pharma in the NASDAQ 100?
No, Lantern Pharma is not included in the NASDAQ 100 index
Is Lantern Pharma in the Dow Jones?
No, Lantern Pharma is not included in the Dow Jones index
When was Lantern Pharma the previous earnings report?
No data
When does Lantern Pharma earnings report?
The next expected earnings date for Lantern Pharma is 08 November 2024